Some of the world’s largest pharmaceutical and medical companies have returned to the U.S. Supreme Court in an attempt to overturn a ruling allowing American servicemembers, civilians, and their families to pursue allegations that company payments and medical goods helped finance terrorist attacks in Iraq.

Originally filed in 2017, the case involves AstraZeneca, Pfizer, Johnson & Johnson, Roche, Genentech, and GE Healthcare-related companies.

The plaintiffs assert that for nearly a decade, the companies paid millions of dollars in cash and in-kind bribes and supplied extra, off-the-books quantities of medicines and medical products through Iraq’s Ministry of Health at a time when it was allegedly under the control of Jaysh al-Mahdi, a militia blamed for deadly attacks on Americans. They also allege that Hezbollah, which is designated by the United States as a Foreign Terrorist Organization, planned or authorized the relevant attacks carried out by Jaysh al-Mahdi.

The companies strongly dispute the plaintiffs’ legal case and say they were supplying legitimate medicines and medical equipment to Iraq during a U.S.-backed reconstruction effort. They argue that the plaintiffs cannot link specific company payments or products to particular terrorist attacks and have not adequately shown that the companies intended to aid those attacks.

The allegations have not been proven at trial. But in January 2026, the U.S. Court of Appeals for the District of Columbia Circuit ruled that they were sufficiently detailed and plausible for the lawsuit to continue. Remarkably, the appeals court reached that conclusion after the Supreme Court had already sent the case back once for reconsideration.

Cash, Drugs, and the “Pill Army”

At the heart of this case is a fundamental disagreement over what was really happening inside Iraq’s Ministry of Health during the period in question. The pharmaceutical companies portray themselves as businesses supplying badly needed medicines and medical equipment to an official Iraqi government agency. Their Supreme Court petition says the United States government was encouraging private companies to help rebuild Iraq’s healthcare system at the time following the fall of Saddam Hussein.

The plaintiffs tell a very different story. In their 7 October 2026 response to the Supreme Court, they allege that Jaysh al-Mahdi had effectively taken control of the Iraqi Ministry of Health and that the companies secured lucrative contracts by making corrupt payments to officials associated with the militia. They say their complaint identifies specific contracts, alleged bribe amounts, local agents, and quantities of additional “free goods.”

According to the plaintiffs, some of those extra goods consisted of off-the-books batches of medicines and other medical products that were shipped alongside goods that had actually been purchased. They allege that these products were packaged in ways that made them easy to resell and that ministry officials did not have to account for them.

The plaintiffs say Jaysh al-Mahdi could then sell the goods on the black market to raise money or even use the medicines themselves as a form of payment to fighters. According to the court filings, the militia became so dependent on resources from the health ministry that it was reportedly known in Iraq as the “Pill Army.”

These remain allegations. But they are far more specific than a simple claim that ordinary medicines somehow ended up in the wrong hands.

What Exactly Did the Companies Know?

One of the most important questions in the case concerns what the companies allegedly knew about Jaysh al-Mahdi’s control of the Iraqi health ministry. The plaintiffs claim this control was highly visible. Their Supreme Court filing says militia propaganda and flags were displayed at ministry facilities, fighters patrolled the halls, and that a 2006 U.S. Embassy report described the ministry and its infrastructure as openly under Jaysh al-Mahdi’s control.

The plaintiffs further allege that the companies had local agents, security departments, and compliance systems that would have exposed them to reporting about the militia’s activities.

But the companies reject the conclusion the plaintiffs draw from this. Their argument is essentially that even if corruption and diversion occurred, that does not mean pharmaceutical companies intended to help terrorist attacks succeed. Their commercial objective, say the companies, was to sell medical products and participate in Iraq’s reconstruction, not to support terrorism.

In their 21 October 2026 reply, the companies went further, explicitly rejecting the allegation that they intended to help finance attacks on Americans. This is one of the central legal disputes now before the Supreme Court.

Must victims show that a company actually wanted to help the terrorist attacks succeed? Or can liability arise where a company knowingly provides substantial assistance while allegedly knowing that the assistance will help finance terrorism? Questions such as these lie at the heart of the companies’ request for Supreme Court review.

The plaintiffs say the law does not require proof that a company positively wanted an attack to take place. Instead, they argue that the courts must look at what the company knew, the nature of the assistance it allegedly provided, and how substantial that assistance was.

The Supreme Court Sent the Case Back – But It Survived

The unusual history of the case makes this latest Supreme Court battle especially significant. The lawsuit was originally dismissed by a lower court, but in 2022 the D.C. Circuit revived it. Subsequently, the pharmaceutical companies asked the Supreme Court to review the ruling.

In 2024, the Supreme Court vacated the appeals court’s earlier ruling and ordered it to reconsider the case in light of a separate terrorism case, Twitter v. Taamneh. That ruling had placed important limits on when companies can be held responsible for allegedly aiding terrorism. For the pharmaceutical companies, this appeared to be a major victory. But it did not end the case.

After reconsidering the allegations under the Supreme Court’s Taamneh standard, the D.C. Circuit ruled again in January 2026 that the lawsuit could proceed. The court concluded that the allegations went considerably further than merely claiming that companies had provided ordinary services later exploited by terrorists. The complaint instead alleged that repeated cash payments and supplies of extra medical goods were structured in an unusual and allegedly unlawful way that helped Jaysh al-Mahdi finance its operations.

As a result, the companies are now asking the Supreme Court to intervene for a second time. Their 21 August 2026 petition argues that the appeals court has gone too far. In particular, they stress that the plaintiffs cannot trace any individual payment or box of medicines to a particular attack that injured a specific plaintiff. They also argue that the D.C. Circuit’s approach conflicts with decisions from other federal appeals courts, particularly the Second Circuit, which they say has required a closer connection between alleged assistance and terrorist attacks.

On 21 October 2026, the companies filed a reply brief defending their request for Supreme Court review. They again argued that the plaintiffs have failed to link particular company payments or medical supplies to specific terrorist attacks and have not shown that the companies intended to help those attacks succeed. They also maintain that the D.C. Circuit’s approach conflicts with rulings from other federal appeals courts.

The plaintiffs respond that this misrepresents their case. They insist they are not relying on a vague theory that money somehow found its way to terrorists. Instead, they say that the companies knowingly made payments and supplied valuable goods to a ministry controlled by the very organization that was responsible for terrorist attacks in Iraq. They also reject the companies’ claim that the D.C. Circuit has created a major conflict with other federal appeals courts, arguing that previous cases cited involved materially different allegations.

Nine Years of Litigation

There is also a human dimension to this legal battle. The plaintiffs point out that the case has now been running for nine years and that 51 of the respondents have died while it has been pending. They have also told the Supreme Court that the evidence-gathering stage of the case, known as discovery, is finally underway. Discovery can potentially involve internal corporate documents, communications, contracts, payment records, and testimony, depending on what the lower court permits.

The plaintiffs therefore argue that the Supreme Court should not interrupt the case again at this preliminary stage. They say the companies will have opportunities later to challenge the evidence and defend themselves if the case continues.

For their part, the companies suggest that allowing the lawsuit to proceed could have wider consequences. They say businesses and humanitarian organizations may become reluctant to operate in unstable countries if they risk being held responsible whenever corrupt officials or terrorist groups later misuse legitimate goods or payments. That broader policy argument could prove important when the Supreme Court decides whether to hear the case.

A Major Story Few People Have Heard About

Whatever the eventual outcome, the allegations in this case are extraordinary. American servicemembers and families are accusing some of the world’s largest pharmaceutical companies of providing money and valuable medical goods that allegedly helped sustain an armed militia responsible for deadly attacks on Americans in Iraq.

The companies deny that their legitimate business activities amount to support for terrorism and say that the D.C. Circuit has stretched U.S. anti-terrorism law too far.

Regardless, the Supreme Court has now distributed the case for consideration at its 6 November 2026 conference, when the Justices are expected to consider whether to hear the challenge.

Yet despite the household-name corporations involved, the seriousness of the allegations, and the fact that the companies have now returned to America’s highest court, this latest Supreme Court battle appears to have attracted remarkably little attention from the mainstream media.

For a case involving alleged terrorist financing, American military casualties, multinational pharmaceutical companies, and the U.S. Supreme Court, the lack of media attention to this latest development is striking.

*

Click the share button below to email/forward this article. Follow us on Instagram and X and subscribe to our Telegram Channel. Feel free to repost Global Research articles with proper attribution.

This article was originally published on Dr. Rath Health Foundation.

Executive Director of the Dr. Rath Health Foundation and one of the coauthors of our explosive book, “The Nazi Roots of the ‘Brussels EU’”, Paul is also our expert on the Codex Alimentarius Commission and has had eye-witness experience, as an official observer delegate, at its meetings. You can find Paul on Twitter at @paulanthtaylor

He is a regular contributor to Global Research. 

Featured image is from the author/AI-generated

Global Research is a reader-funded media. We do not accept any funding from corporations or governments. Help us stay afloat. Click the image below to make a one-time or recurring donation.